

| | |
|-------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1. Record Nr. | UNINA9910876527503321 |
| Autore | Lamprou Dimitrios A. |
| Titolo | 3D Printing of Pharmaceutical and Drug Delivery Devices : Progress from Bench to Bedside |
| Pubbl/distr/stampa | Newark : , : John Wiley & Sons, Incorporated, , 2024 ©2024 |
| ISBN | 1-119-83600-X 1-119-83598-4 1-119-83599-2 |
| Edizione | [First eddition.] |
| Descrizione fisica | 1 online resource (265 pages) |
| Collana | Advances in Pharmaceutical Technology Series |
| Altri autori (Persone) | DouroumisDennis QiSheng |
| Disciplina | 615.19 |
| Lingua di pubblicazione | Inglese |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Nota di contenuto | Intro -- 3D Printing of Pharmaceutical and Drug Delivery Devices -- Contents -- About the Editors -- List of Contributors -- Series Preface -- Preface -- 1 Materials for 3D Printing -- 1.1 Introduction -- 1.2 Material Processability Considerations for Pharmaceutical 3DP -- 1.2.1 Thermal Extrusion-Based 3D Printing -- 1.2.1.1 Thermal Considerations -- 1.2.1.2 Solubility Enhancement -- 1.2.1.3 Mechanical Considerations -- 1.2.2 Semi-Solid Extrusion 3DP -- 1.2.2.1 Rheological Considerations -- 1.2.2.2 Example Applications -- 1.2.3 Powder Bed Fusion 3D Printing -- 1.2.3.1 Powder Flowability Considerations -- 1.2.3.2 Powder Packing Density Considerations -- 1.2.3.3 Powder Energy Absorbance Considerations -- 1.2.4 Stereolithography 3D Printing -- 1.3 Classification of Common Materials Used in Pharmaceutical 3DP -- 1.3.1 Alcohol Derived Polymers -- 1.3.2 Eudragits -- 1.3.3 Other Polymers -- 1.3.4 Graft Polymers -- 1.3.5 Photocrosslinkable -- 1.3.6 Natural Materials -- 1.3.7 Lipid Materials -- 1.4 Conclusions and Future Perspectives -- References -- 2 The Use of Microstructure Design and 3D Printing for Tailored Drug Release -- 2.1 Introduction -- 2.2 3D-Printing Technologies -- 2.3 3D Design for Drug-Loaded Device -- 2.3.1 CAD |

Design-Based Design -- 2.3.2 Computational Software-Based Design -- 2.3.3 3D-Printing Parameter-Based Design -- 2.3.4 Polypills and Complex Designs -- 2.4 3D Designs Influence Drug Release -- 2.4.1 Controlling Drug Release -- 2.4.2 Modifying Drug Release -- 2.5 Challenges and Perspective -- References -- 3 3D Printing of Oral Solid Dosage Forms Using Selective Laser Sintering -- 3.1 Introduction -- 3.2 Operational Principles of Selective Laser Sintering -- 3.2.1 Manufacturing Challenges for SLS -- 3.2.2 Laser Selection and Scanning Speed -- 3.2.3 Powder Material Parameters -- 3.2.4 Powder Bed and Recoater Parameters.

3.3 3D-Printed Oral Dosages -- 3.4 Advantages of SLS -- 3.4.1 Printing Features -- 3.4.2 Control of Surface Properties -- 3.4.3 Printing of Complex Geometries -- 3.4.4 Using a Wide Range of Materials -- 3.4.5 Drug Loading and Dose Combinations -- 3.4.6 Personalised Dosage Forms -- 3.4.7 SLS Disadvantages -- 3.5 Conclusions -- References -- 4 3D Printing for Medical Device Applications -- 4.1 Introduction -- 4.2 3D Printers -- 4.2.1 SLA -- 4.2.2 FFF -- 4.2.3 Selective Laser Sintering (SLS) -- 4.3 Biomaterials for 3D-Printed Medical Devices -- 4.3.1 Bioresorbable Polymers -- 4.3.1.1 Synthetic Bioresorbable Polymers -- 4.3.1.2 Natural Bioresorbable Polymers -- 4.3.2 Non-Bioresorbable Polymers -- 4.3.3 Smart Polymers -- 4.3.4 Metal and Ceramic -- 4.4 3D-Printed Personalised Medical Devices -- 4.4.1 Vascular Repair Devices -- 4.4.2 Splints -- 4.4.3 Nerve Guidance Conduits -- 4.4.4 Tissue Engineering -- 4.4.5 3D Printing in Dentistry -- 4.4.6 3D-Printed Orthopaedic Devices -- 4.5 Regulatory -- 4.6 Future Perspectives -- References -- 5 3D Printed Implants for Long-Acting Drug Delivery -- 5.1 Introduction -- 5.2 Types of 3D-Printed Scaffolds -- 5.2.1 Implantable Scaffolds -- 5.2.1.1 Passive Implants -- 5.2.1.2 Active Implants -- 5.2.2 Injectable Scaffolds -- 5.2.3 Innovative 3D-Printed Scaffolds -- 5.3 Critical Parameters in Designing 3D-Printed Implantable Scaffolds -- 5.3.1 Structural Characteristics -- 5.3.1.1 Geometry of Implants -- 5.3.1.2 Porosity Properties and Pore Features -- 5.3.1.3 Surface Properties -- 5.3.2 Mechanical Properties -- 5.3.3 Biological and Physiological Parameters -- 5.3.3.1 Cellular Adhesion -- 5.3.3.2 Absorption and Degradation Rates -- 5.3.3.3 Biocompatibility Aspects -- 5.4 Critical Parameters in Selecting Materials for 3D-Printed Scaffolds -- 5.4.1 Materials Used in 3D-Printed Long-Acting Scaffolds -- 5.4.1.1 Natural Polymers.

5.4.1.2 Synthetic Polymers -- 5.4.1.3 Ceramics and Metals -- 5.4.1.4 Composites -- References -- 5.5 Manufacturing Techniques for Implantable Scaffolds -- 5.5.1 Hot-Melt Extrusion -- 5.5.2 Compression -- 5.5.3 Injection Moulding -- 5.5.4 Solvent Casting -- 5.5.5 3D Printing -- 5.5.6 Scale-Up in 3D-Printing Process for the Manufacturing of Scaffolds -- 5.6 Drug Release Mechanism of Long-Acting 3D-Printing Polymeric Implantable Systems -- 5.7 Outlining Regulatory Framework for 3D-Printed Implantable Scaffolds -- 5.7.1 Commercial Implantable Scaffolds -- 5.8 Conclusions -- References -- 6 Wound Dressings by 3D Printing -- 6.1 Wound Healing Process -- 6.1.1 Haemostasis/Coagulation -- 6.1.2 Inflammation -- 6.1.3 Proliferation -- 6.1.4 Re-epithelisation/Remodelling -- 6.1.5 Wound Classification -- 6.1.6 Wound Dressings -- 6.1.7 3D Printing -- 6.1.8 3D-Printed Dressings -- 6.2 Case Studies -- 6.3 Summary/Conclusions -- References -- 7 3D Printing of Hydrogels -- 7.1 Introduction -- 7.2 Applications of 3D-Printed Hydrogels -- 7.2.1 Tissue Engineering -- 7.2.2 Wound Healing -- 7.2.3 Drug Delivery -- 7.3 Types of Hydrogel Materials for 3D Printing -- 7.3.1 Natural Polymers -- 7.3.2 Synthetic Polymers -- 7.3.3 Natural-Synthetic Hybrid Polymers -- 7.3.4 Ionically

Charged Polymers -- 7.3.5 Crosslinked Polymers -- 7.3.6 Method of Hydrogel Preparation -- 7.4 3D Printing Techniques for Hydrogels -- 7.4.1 Laser-Based 3D Printing -- 7.4.1.1 Stereolithography -- 7.4.1.2 Two-Photon Polymerisation -- 7.4.1.3 Laser-Induced Forward Transfer -- 7.4.2 Extrusion-Based Printing -- 7.4.3 Inkjet-Based Printing -- 7.5 Printability and Printing Parameters -- 7.5.1 Bioink Design -- 7.5.1.1 Materials Selection, Concentration and Viscosity -- 7.5.1.2 Rheological Properties -- 7.5.1.3 Shear-Thinning -- 7.5.1.4 Viscoelasticity and Yield Stress -- 7.5.1.5 Cell Encapsulation. 7.5.2 Crosslinking Techniques -- 7.5.2.1 Thermal Crosslinking -- 7.5.2.2 Physical Ionic Crosslinking -- 7.5.2.3 Chemical Crosslinking -- 7.5.2.4 Photocrosslinking -- 7.5.3 3D Printing Parameters -- 7.5.3.1 Temperature -- 7.5.3.2 Pressure -- 7.5.3.3 Speed -- 7.6 Clinical Translation -- 7.6.1 Regulatory Considerations -- 7.6.2 Manufacturing Considerations -- 7.6.3 Limitations and Future Direction -- 7.7 Conclusions -- References -- 8 Analytical Characterisation of 3D-Printed Medicines -- 8.1 Introduction -- 8.2 Preformulation -- 8.2.1 Thermal Analysis -- 8.2.2 X-Ray Powder Diffraction (XRPD) -- 8.2.3 Infrared Spectroscopy -- 8.2.4 Hot-Stage Microscopy (HSM) -- 8.2.5 Customized Sample Preparation for the Preformulation Protocol -- 8.3 In-Process Characterisations -- 8.3.1 Mechanical Analysis -- 8.3.2 Rheological Analysis -- 8.3.3 Drug Characterisation -- 8.4 Final Product -- 8.4.1 Morphological Analysis -- 8.4.2 X-Ray Computed Microtomography (XCT) -- 8.4.3 Terahertz Pulsed Imaging (TPI) -- 8.4.4 Mercury Porosimetry -- 8.4.5 Helium Pycnometry -- 8.5 Conclusions -- References -- 9 Adoption of 3D Printing in Pharmaceutical Industry -- 9.1 Partnering and Growing -- 9.2 Regulatory Strategy -- 9.2.1 Product Development -- 9.2.2 Manufacturing -- 9.3 Business Model -- 9.3.1 In-House Pipeline Products -- 9.3.2 Co-Development -- 9.4 Regulatory Strategy -- 9.5 Partnering and Growing -- 9.6 Business Model and Strategy -- 9.6.1 Closing Remarks -- References -- 10 Clinical Benefits of 3D Printing in Healthcare -- 10.1 Introduction -- 10.2 3D Printing Technologies -- 10.2.1 Binder Jetting -- 10.2.2 Vat Photopolymerization -- 10.2.3 Powder Bed Fusion -- 10.2.4 Material Jetting -- 10.2.5 Material Extrusion -- 10.2.5.1 Fused Deposition Modelling -- 10.2.5.2 Semi-Solid Extrusion -- 10.2.5.3 Direct Powder Extrusion -- 10.3 Preclinical Applications of 3D Printing. 10.3.1 Immediate and Modified Release Oral Printlets -- 10.3.2 3D-Printed Drug Delivery Devices for Other Routes of Administration -- 10.4 Clinical Applications of 3D Printing -- 10.4.1 Personalised Medications -- 10.4.2 Improved Acceptability and Medication Compliance -- 10.4.2.1 Paediatric Patients -- 10.4.2.2 Adult and Geriatric Patients -- 10.4.3 Mass Manufacturing -- 10.4.4 Decentralised On-Demand Fabrication -- 10.4.5 Veterinary Applications -- 10.5 Challenges, Regulatory View and Future Applications -- 10.6 Conclusion -- References -- 11 Regulatory Aspects of 3D-Printed Medicinal Products -- 11.1 Introduction -- 11.2 Current Regulatory Framework -- 11.3 Quality Aspects of 3D-Printed Medicinal Products -- 11.4 3D-Printed Paediatric Medicinal Products -- 11.5 3D-Printed Systems With Tailored Release Profiles -- 11.6 Conclusions -- Disclaimer -- References -- Index -- EULA.
